auto-immune diseases
Conditions
Interventions
Twelve volunteers will receive 10 capsules of 0,5 µg calcitriol, the other twelve volunteers will receive 10 capsules placebo. They have to take the medication twice a day during 5 days.
Sponsors
dr. E.M.W. Eekhoff
endocrinology
Vu university medical centre
De Boelelaan 1118
1081 HV
Netherlands
Tel:+31-20-4440533
Fax:+31-20-4440502
emw.eekhoff@vumc.nl
Eligibility
Inclusion criteria
Inclusion criteria: 1. Written informed consent; 2. women, aged 20-30 years; 3. use of oral contraception with estrogen and progestin; 4. apparently health.
Exclusion criteria
Exclusion criteria: 1. Men; 2. pregnancy; 3. smoking; 4. alcohol abuse: > 3 Units/day; 5. use of drugs, except for incidental analgesic agents; 6. use of diuretic medication or corticosteroids; 7. auto immune diseases; 8. renal impairment (serum creatinine >150 µmol/l); 9. malignant disease; 10. kidney-stones (also when this occurs in the family), urinary tract infections; 11. infectious diseases; 12. use of antibiotics; 13. use of any medication that influence T- lymphocytes or vitamin D metabolism; 14. disease or use of any medication known to affect Ca metabolism or skeletal physiology; 15. serious mental impairment i.e. preventing to understand the study protocol/aim.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We expect the serum level of 1,25(OH)2D3 to rise and to induce the activity of T lymphocytes and the dendritic cells which regulate the immunity and reduce the activity of type 1 T lymphocytes involved in auto-immune diseases. Their activity will be measured by the decrease of interferon gamma production. | — |
Secondary
| Measure | Time frame |
|---|---|
| We expect the type 1 cytokines to be decreased and the type 2 cytokines to be upregulated. | — |
Contacts
Public ContactC.M. Dinkgreve
VU University Medical Center, Department of endocrinology De Boelelaan 1118
Outcome results
None listed